透皮
安慰剂
透皮贴片
血管舒缩
医学
不利影响
雌激素
皮肤贴
刺激
更年期
药品
药理学
内科学
麻醉
皮肤病科
免疫学
替代医学
病理
作者
S F Gordon,K A Thompson,GARY E. RUOFF,J R Imig,P J Lane,C E Schwenker
出处
期刊:PubMed
[National Institutes of Health]
日期:1995-05-01
卷期号:40 (3): 126-34
被引量:18
摘要
OBJECTIVE: To evaluate the efficacy and safety of a new, seven-day, transdermal estradiol system in healthy postmenopausal women with hot flushes. METHODS: Two studies are described. In the first study, subjects were randomized to treatment with a 0.05 mg/day estradiol patch, a 0.1 mg/day estradiol patch, or a placebo patch; and in the second study, to treatment with either of the two estradiol patches or oral conjugated estrogens (as Premarin) 0.625 mg/day. Efficacy was evaluated on the basis of diary entries recording hot-flush frequency and severity. Subjects' and investigators' global assessments of treatment efficacy were recorded at follow-up visits. RESULTS: In Study 1, both the 0.05-mg and 0.1-mg estradiol patches were significantly more effective than placebo in reducing hot flushes and were associated with higher global assessments. In Study 2, all three active treatments produced a significant reduction in the number of hot flushes compared with base-line. There were no statistically significant between-group differences, although the response to the 0.1-mg estradiol patch was greater, and to the 0.05-mg estradiol patch less, than the response to conjugated estrogens. The patches were generally well tolerated. Skin irritation from the patch was the most common adverse experience in both studies. CONCLUSIONS: The new, seven-day, transdermal system effectively and safely treats post-menopausal vasomotor symptoms.
科研通智能强力驱动
Strongly Powered by AbleSci AI